Sort   by:  
 Page size 
MetabolomicsMethionine Intervention Induces PD-L1 Expression to Enhance the Immune Checkpoint Therapy Response in MTAP-deleted Osteosarcoma
Osteosarcoma (OS), a malignant bone tumor with limited treatment options, exhibits low sensitivity to immune checkpoint therapy (ICT). Through genomics and transcriptomics analyses, we have identified a subgroup of OS with methylthioadenosine phosphorylase (MTAP) deletion, which contributes to ICT r...
2026-06-09 | MTBLS11985 | MetaboLights
UnknownPeptide Lv augments L-type voltage-gated calcium channels through vascular endothelial growth factor receptor 2 (VEGFR2) signaling.
Not available
S-EPMC4382007 | biostudies-literature
UnknownIdentification of Peptide lv, a novel putative neuropeptide that regulates the expression of L-type voltage-gated calcium channels in photoreceptors.
Not available
S-EPMC3418253 | biostudies-literature
ClinicalA Trial Comparing Adjuvant Oral UFT/LV to 5-FU/l-LV in Stage III Colorectal Cancer (JCOG-0205-MF)
To evaluate the clinical effectiveness of oral UFT/LV comparing 5-FU/l-LV as adjuvant therapy for stage III colorectal cancer.
2018788 | ecrin-mdr-crc
TranscriptomicsRabbit heart gene expression in Left ventricle (LV) following banding of the descending thoracic aorta (AOB-LV) vs Sham-control LV and in Right ventricle (RV) following banding the pulmonary artery (PAB-RV) vs. Sham-control RV
Background: Right ventricular (RV) and left ventricular (LV) myocardium differ in their response to pressure-overload hypertrophy (POH). In this report we use microarray and proteomic analyses to identify pathways modulated by LV-, and RV-POH in the immature heart. Methods: Newborn New Zealand White...
ORGANISM(S): Oryctolagus cuniculus 
2011-06-24 | E-GEOD-30194 | biostudies-arrayexpress
ClinicalPhase I / II Study of Irinotecan (CPT-11) Combined With l-Leucovorin (l-LV) and 5-FU in Patients With Advanced Colorectal Cancer
We performed a phase I/II study of CPT-11/5FU/l-LV in advanced colorectal cancer, to determine the optimal dose of CPT-11 and to estimate the safety and efficacy of this regimen
2020221 | ecrin-mdr-crc
UnknownBiodegradation of di-n-butyl phthalate by bacterial consortium LV-1 enriched from river sludge.
Not available
S-EPMC5444784 | biostudies-literature
ClinicalPhase II study of a combination of CPT-11, 5FU/l-LV and UFT/LV in patients with advanced/recurrent colorectal cancer
Interventions: It takes 2 weeks for one course and that is to be repeated. Dose schedule for one course CPT-11 150mg/ m2/day Day 1 5-FU 500 mg/m2/day Day 1 l-LV 15 mg/m2/day Day 1 UFT 300 mg/m2/day Day 1-8 morning LV 75 mg/day Day 1-8 morning Primary outcome(s): response rate Study Design: Single ar...
2616118 | ecrin-mdr-crc
ClinicalSafety and efficacy of postoperative adjuvant chemotherapy with L-OHP base regimen followed by UFT plus LV for resectable liver metastases from colorectal cancer
Interventions: Postoperative adjuvant chemotherapy with L-OHP base regimen (6courses of mFOLFOX6 or 4courses of CapeOX) followed by 3courses of UFT plus LV. Primary outcome(s): the completion rate Study Design: Single arm Non-randomized
2635906 | ecrin-mdr-crc
ClinicalPhase II study of a combination of modified CPT-11 and 5-FU/l-LV (mJIFL) in patients with meatastatic colorectal cancer
Interventions: On Day 1, 8, 15, CPT-11 100 mg/m2 l-LV 250 mg/m2 administered simultaneously 5-FU 500 mg/m2 administered subsequently ** It takes 28 days for the one course. ** More than two courses are required. Primary outcome(s): Response Rate Study Design: Single arm Non-randomized
2616231 | ecrin-mdr-crc
Sort   by:  
 Page size